

Public Assessment Report

Scientific discussion

Brimonidine axunio

(brimonidine tartrate)

SE/H/1652/01/DC

This module reflects the scientific discussion for the approval of Brimonidine axunio. The procedure was finalised on 2017-10-04. For information on changes after this date please refer to the module 'Update'.

I. INTRODUCTION

The application for Brimonidine axunio, eye drops, solution, 2 mg/ml, is a hybrid application made according to Article 10(3) of Directive 2001/83/EC. The applicant, axunio Pharma GmbH, applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and DE as concerned member states (CMS).

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Alphagan 0,2% (2 mg/ml), eye drops, solution authorised in Sweden since 1997, with Allergan Pharmaceuticals Ireland as marketing authorisation holder.

For recommendations to the marketing authorisation not falling under Article 21a/22 of Directive 2001/83 and conditions to the marketing authorisation pursuant to Article 21a or 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

N/A

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

IV.3 Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Brimonidine axunio.

Safety specification

Summary table of safety concerns in RMP, v2.0, with sign off 15 Feb 2017, submitted by the Applicant is presented below:

Important identified risks	• Hypersensitivity • Central nervous system depression in children • Heart and circulatory disorders • Damage to the corneal epithelium due to use of eye drops containing preservatives
Important potential risks	• Accidental overdose/ingestion in children
Missing information	• Use in pregnant women • Use in breastfeeding mothers • Use in patients with hepatic and renal impairment

The RMP proposed by the Applicant is in line with the RMP of the recently approved hybrid product with the same composition and indication

Pharmacovigilance Plan

Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Risk minimisation measures

Routine risk minimisation is suggested and no additional risk minimisation activities are proposed by the applicant, which is endorsed.

Summary of the RMP

The RMP is approved.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the RMS;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference regarding **content** to:

1: BRIMONIDINE TARTRATE 0.2% w/v Eye drops, assessed and accepted in UK Public Assessment Report (PAR) for PL number: 15872/0018.

and

2: to the originator Alphagan 0.2% w/v (2 mg/ml) eye drops, solution assessed and accepted in the UK Public Assessment Report (PAR) for PL number: 15872/0018 (UK/H/199/01/II/36).

A user consultation with target patient groups on the package information leaflet (PIL) has also been performed on the basis of a bridging report making reference regarding **layout** to the company house style.

The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the hybrid product, Brimonidine axunio is found adequate. There are no objections to approval of Brimonidine axunio, from a non-clinical and clinical point of view. The product information is acceptable.

The application is therefore recommended for approval.

List of recommendations not falling under Article 21a/22 of Directive 2001/83 in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

Decentralised procedure for Brimonidine axunio, eye drops, solution, 2 mg/ml was positively finalised on 2017-10-04.

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected	Date of end of procedure	Approval/non approval	Summary/Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)